Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly will add 12.5 mg and 15 mg single-dose vials of its weight loss drug Zepbound to its LillyDirect platform starting July 7, completing the full range of approved doses. All vial doses, ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

In 2024, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound generated $8 billion and $4.9 billion, respectively. So, this is approximately a $15 billion market ... loss is its impact on meaningful ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... chiefly that it was not a blinded analysis and participants knew which medication they ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA asset tirzepatide, respectively sold under the brand names Zepbound and ...

Recent data shows Eli Lilly's stock price has surged due to strong demand for its weight-loss drug Zepbound, with first-quarter 2024 ... In terms of cross-market impact, institutional investors often ...

On Tuesday, Bernstein analysts maintained a positive outlook on Eli Lilly (NYSE: LLY) shares, reiterating their Outperform rating and a price target of $1,100.00.The pharmaceutical giant ...